Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, has entered into a global strategic services agreement with QuintilesIMS, a leading provider of biopharmaceutical development and commercial outsourcing services.
The services agreement establishes an operational platform to facilitate Verona Pharma’s global clinical trial-related activities for the development of its product candidate RPL554 for the treatment of COPD (chronic obstructive pulmonary disease) and cystic fibrosis and for future commercialisation initiatives.
Pursuant to the agreement, Quintiles will serve as sole provider of core clinical trial services for Verona Pharma’s RPL554 clinical development programmes.
Verona Pharma will have full access to Quintiles’ therapeutic and operational experts throughout the duration of each trial, from the planning and design through to execution.
Joint governance and quality oversight has been established to ensure strategic and operational goals are met and compliance with regulatory and quality requirements. Verona Pharma will also have access to QuintilesIMS’ global commercial insights when developing its market access strategy in the United States for RPL554.
Verona Pharma’s product candidate, RPL554, is an inhaled, dual PDE3/PDE4 inhibitor that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
Verona Pharma is currently developing RPL554 for the maintenance treatment of COPD patients and as an add-on therapy to commonly used therapies for the treatment of hospitalised patients with acute exacerbations of COPD. It is also developing RPL554 for the treatment of patients with cystic fibrosis.
Dr Jan-Anders Karlsson, Verona Pharma’s Chief Executive Officer, commented: “Verona Pharma is focused on advancing the clinical development of RPL554 for the treatment of COPD and cystic fibrosis.”
“The company has already completed eight Phase I and IIa clinical trials for RPL554, and we believe that our strategic services agreement with QuintilesIMS will enhance the agility, productivity and commercial viability of our development activities as we progress multiple larger and later-stage clinical trials.”